FDA looking at possible Singulair suicidality connection

Share this article:
The FDA issued an early communication advising that it is investigating a possible risk of suicidality with Merck's allergy and asthma drug Singulair.

“FDA is working with Merck to further evaluate a possible link between the use of Singulair and behavior/mood changes, suicidality and suicide in response to inquiries received by FDA,” said the agency, estimating that it will take up to 9 months to complete its evaluation of the issue. The agency said it has advised Merck to reevaluate Singulair study data and is reviewing the relevant postmarketing reports.

Over the past year, Merck has updated prescribing information and patient information for the drug to advise of post-marketing adverse events including tremor, depression, suicidality and anxiousness.

FDA is also looking into similar postmarketing reports for other leukotriene modifying medications, including AstraZeneca's Accolate and Zyflo/Zyflo CR, from Dey and Critical Therapeutics.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...